EXTH-15. TARGETING ANDROGEN SIGNALING IN GLIOBLASTOMA (GBM) USING SEVITERONEL (SEVI), A CYP17 LYASE AND ANDROGEN RECEPTOR (AR) INHIBITOR, ALONE AND IN COMBINATION WITH RADIATION (RT)

Lignende værker

• Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
  af: Michmerhuizen, Anna R., et al.
  Udgivet: (2020)
• Seviteronel, a Novel CYP17 Lyase Inhibitor and Androgen Receptor Antagonist, Radiosensitizes AR-Positive Triple Negative Breast Cancer Cells
  af: Anna R. Michmerhuizen, et al.
  Udgivet: (2020-02-01)
• A population pharmacokinetic analysis of the oral CYP17 lyase and androgen receptor inhibitor seviteronel in patients with advanced/metastatic castration-resistant prostate cancer or breast cancer
  af: Peer, Cody J., et al.
  Udgivet: (2019)
• Phase 1 Study of Seviteronel, a Selective CYP17 Lyase and Androgen Receptor Inhibitor, in Women with Estrogen Receptor-positive or Triple-negative Breast Cancer
  af: Bardia, Aditya, et al.
  Udgivet: (2018)
• Expression of the of the androgen receptor governs radiation resistance in a subset of glioblastomas vulnerable to anti-androgen therapy
  af: Werner, Christian K., et al.
  Udgivet: (2020)